# Ergomed PLC -.1% potential downside indicated by Investec Securities

- Link: https://www.directorstalkinterviews.com/ergomed-plc.1-potential-downside-indicated-by-investec-securities/4121127487
- Published: 2023-09-19T13:39:31+01:00
- Author: Charlotte Edwards

**Ergomed PLC** with ticker (LON:ERGO) now has a potential downside of -.1% according
to Investec Securities.
Investec Securities set a target price of 1,350 GBX for 
the company, which when compared to the Ergomed PLC share price of 1,352 GBX at 
opening today (19/09/2023) indicates a potential downside of -.1%. Trading has ranged
between 895 (52 week low) and 1,380 (52 week high) with an average of 495,766 shares
exchanging hands daily. The market capitalisation at the time of writing is £686,583,221.
Ergomed PLC is a United Kingdom-based company that is primarily focused on providing
specialized services to the biopharmaceutical industry. The Company operates through
two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). Its CRO
segment is the process of developing medical therapies, drugs and knowledge for 
safe use in healthcare. Its PV segment is engaged in the activities relating to 
the detection, understanding and prevention of adverse effects or other drug-related
problems throughout its lifecycle. The Company serves over 100 countries. It operates
in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The
Company’s subsidiaries include PrimeVigilance Inc., PrimeVigilance USA Inc., PrimeVigilance
s.r.o., PharmInvent regulatory s.r.o., PrimeVigilance Japan K.K., Haemostatix Limited
and Sound Opinion Limited.

Share on: